Related Experiment Video

Updated: Mar 3, 2026

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.6K

No relation between biomarkers at age 47-49 and aortic diameter after 14-19 years of follow-up - a population-based

Soumia Taimour1, Moncef Zarrouk1, Jan Holst1

  • 11 Department of Vascular Diseases, Lund University, Malmö, Sweden.

VASA. Zeitschrift Fur Gefasskrankheiten
|April 28, 2017
PubMed

Insights

Biomarker levels in middle-aged men did not predict abdominal aortic aneurysm (AAA) development over 14-19 years. These biomarkers may become relevant closer to AAA diagnosis, not in early detection.

Area of Science:

  • Cardiovascular research
  • Atherosclerosis and vascular disease
  • Biomarker discovery

Background:

  • Abdominal aortic aneurysm (AAA) pathogenesis involves diverse pathophysiological pathways.
  • Elevated biomarker levels correlate with aortic diameter in older men screened for AAA.

Purpose of the Study:

  • To investigate the long-term relationship between specific biomarkers and aortic dilatation.
  • To assess if early-life biomarker levels predict future aortic diameter in a population-based cohort.

Main Methods:

  • Prospective, population-based cohort study of 117 men aged 47-49.
  • Measured baseline levels of C-reactive protein (CRP), proneurotensin (PNT), copeptin (CPT), lipoprotein-associated phospholipase 2 (Lp-PLA2), cystatin C (Cyst C), midregional proatrial natriuretic peptide (MR-proANP), and midregional proadrenomedullin (MR-proADM).
  • Related biomarker levels to aortic diameter measured via ultrasound 14-19 years later.

Main Results:

  • No significant correlations were found between baseline biomarker levels and aortic diameter after 14-19 years.
  • Linear regression adjusting for age and smoking also showed no significant associations.
  • Specific correlation coefficients (r) ranged from -0.156 to 0.153 for the tested biomarkers.

Conclusions:

  • Biomarker levels measured in early adulthood are not associated with aortic diameter in later life.
  • The predictive value of these biomarkers for aortic dilatation may emerge closer to the clinical diagnosis of AAA.
  • Further research is needed to identify biomarkers relevant for early AAA risk prediction.
Abstract

Keywords:
Biomarkersaortic aneurysmaortic diameter

More Related Videos

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology09:33

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology

Published on: February 7, 2015

16.9K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

Related Concept Videos

Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
701
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
658
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
654
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K